Ocular Therapeutix outlines superiority trial milestones and broad diabetic label strategy as cash runway extends into 2028 (NASDAQ:OCUL)

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]